A Phase 1, Open-Label Study in Healthy Subjects to Evaluate the Absolute Bioavailability of AG-221 by a Microtracer Approach

INTRODUCTION: The purpose of this study was to evaluate the absolute bioavailability (BA) of AG-221 following a single oral dose of 100 mg AG-221 and an intravenous (IV) dose of ~ 100 μg AG-221 containing approximately 300 nCi of [(14)C]-AG-221. METHODS: This was a phase 1, open-label study. Six sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaomin, Chen, Jian, Reyes, Josephine, Zhou, Simon, Palmisano, Maria, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360017/
https://www.ncbi.nlm.nih.gov/pubmed/32700065
http://dx.doi.org/10.1007/s40487-019-0097-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360017/
https://www.ncbi.nlm.nih.gov/pubmed/32700065
http://dx.doi.org/10.1007/s40487-019-0097-7

Ejemplares similares